ASH Annual Meeting & Exposition CAR-T | Conference

Yael Cohen, MD, on Entering an Era of CAR T-Cell Therapy for Myeloma
January 28, 2022

Yael Cohen, MD, sat down with CancerNetwork® to discuss how the multiple myeloma space is entering into an era of CAR T-cell therapy.

Yael Cohen, MD, on the Safety Profile of Cilta-Cel in Refractory Myeloma
January 27, 2022

Yael Cohen, MD, discusses safety data from a clinical trial assessing the use of ciltacabtagene autoleucel in lenalidomide-refractory multiple myeloma.

Yael Cohen, MD, on MRD Negativity Following Treatment With Cilta-Cel in Refractory Myeloma
January 24, 2022

In an interview with CancerNetwork®, Yael Cohen, MD, discusses how treatment with ciltacabtagene autoleucel resulted in a high rate of minimal residual disease negativity in patients diagnosed with lenalidomide-refractory multiple myeloma.

Jakubowiak on Future Promise of Cilta-Cel Across Settings in Multiple Myeloma at 2021 ASH
January 20, 2022

Looking forward, Andrzej Jakubowiak, MD, PhD, anticipates CAR T-cell therapy with ciltacabtagene autoleucel will establish its place across various indications for multiple myeloma.

Yael Cohen, MD, on Background for and Key Findings from the Updated CARTITUDE-2 Trial With Cilta-Cel in Refractory Myeloma
January 18, 2022

CancerNetwork®, sat down with Yael Cohen, MD, to discuss the research that lead up to the phase 2 CARTITUDE-2 trial, examining the use of ciltacabtagene autoleucel for those with lenalidomide–refractory multiple myeloma

Jakubowiak on Responses in Subgroups of Patients With Myeloma Who Received Cilta-Cel
January 14, 2022

In an interview at the 2021 ASH Annual Meeting, Andrzej Jakubowiak, MD, PhD, dives into response outcomes in different patient subsets of the phase 1/2b CARTITUDE-1 trial of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma.

Jakubowiak Talks CAR T-Cell Therapy in Heavily Pretreated Myeloma at 2021 ASH
January 10, 2022

In an interview at the 2021 ASH Annual Meeting, Andrzej Jakubowiak, MD, PhD, describes how CAR T-cell therapy for patients with heavily pretreated myeloma has the potential significantly impact response and survival outcomes.

Cilta-Cel Yields Survival Benefit in Triple-Class R/R Multiple Myeloma
December 15, 2021

Patients with triple-class relapsed/refractory multiple myeloma treated with ciltacabtagene autoleucel saw a greater survival benefit over physician's choice of treatment.

Safety, Efficacy of Cilta-Cel in Pretreated Myeloma Maintained in Subgroups Analyses
December 15, 2021

Most subgroups of patients with relapsed or refractory, heavily pretreated multiple myeloma showed durable responses at the 2-year follow-up to the CARTITUDE-1 trial.

Single Infusion Cilta-cel Produces Strong Response Rate in Heavily Pretreated Myeloma Refractory to Lenalidomide
December 15, 2021

Deep responses were seen with single infusion ciltacabtagene autoleucel for heavily pretreated patients with multiple myeloma who were refractory to lenalidomide.